Jeffrey Stein
Chief Executive Officer chez CIDARA THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Jeffrey L.
Stein is the founder of Quorex Pharmaceuticals, Inc. (founded in 1999) and Antibiotics Working Group (founded in 2012).
He held the title of Director, Chief Scientific Officer & Executive VP at Quorex Pharmaceuticals, Inc. in 2005 and Chairman & President at Antibiotics Working Group in 2012-2013.
Dr. Stein's current job(s) include being the President, Chief Executive Officer & Director at Cidara Therapeutics, Inc. since 2014 and an Independent Director at IDEAYA Biosciences, Inc. since 2015.
Dr. Stein's former job(s) include being the President, Chief Executive Officer & Director at Trius Therapeutics, Inc. from 2007-2013, Chairman at Antimicrobials Working Group from 2017-2019, Director-Venture Development at the University of California San Diego in 2005-2006, an Independent Director at Prevacept Infection Control, Inc., Lead Independent Director at Paratek Pharmaceuticals, Inc. from 2014-2023, Principal Scientist at Diversa Corp.
from 1995-2000, and Venture Partner at Sofinnova Investments, Inc. from 2005-2010.
He also held the title of Principal Scientist at The Agouron Institute in 1993-1995.
Dr. Stein's education history includes an undergraduate degree from The California State University in 1979, a graduate degree from The California State University in 1983, a doctorate degree from California Institute of Technology in 1993, and another doctorate degree from the University of California San Diego in 1991.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2024 | 1 527 304 ( 1,69% ) | 1 M $ | 31/03/2024 | |
IDEAYA BIOSCIENCES, INC.
0,01% | 07/06/2023 | 4 281 ( 0,01% ) | 187 850 $ | 31/03/2024 |
Postes actifs de Jeffrey Stein
| Sociétés | Poste | Début |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Chief Executive Officer | 01/01/2014 |
| IDEAYA BIOSCIENCES, INC. | Director/Board Member | 01/10/2015 |
Anciens postes connus de Jeffrey Stein
| Sociétés | Poste | Fin |
|---|---|---|
| PARATEK PHARMACEUTICALS, INC. | Director/Board Member | 21/09/2023 |
Antimicrobials Working Group
 Antimicrobials Working Group Miscellaneous Commercial ServicesCommercial Services Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc. | Chairman | 17/01/2019 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Chief Executive Officer | 01/09/2013 |
| Antibiotics Working Group | Founder | 01/09/2013 |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Corporate Officer/Principal | 01/01/2010 |
Formation de Jeffrey Stein
| The California State University | Undergraduate Degree |
| California Institute of Technology | Doctorate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CIDARA THERAPEUTICS, INC. | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| IDEAYA BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Diversa Corp.
 Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the biotechnology company collects and catalogs the DNA of organisms in diverse environments (from manure piles to tropical islands). A variety of manufacturers license these compounds from the firm to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's products include enzymes for the oil and gas industry | Commercial Services |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Quorex Pharmaceuticals, Inc.
 Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Prevacept Infection Control, Inc.
 Prevacept Infection Control, Inc. Pharmaceuticals: MajorHealth Technology Prevacept Infection Control, Inc. develops and designs pharmaceutical products to eliminate microbial infections. The firm offers B-Lock, an anti-coagulant catheter lock solution with broad spectrum activity against bacterial and fungal microorganisms known to form bio-film structures in indwelling catheters. The company was founded by Krzysztof Appelt and Thomas I. Bradshaw in 2006 and is headquartered in Broomfield, CO. | Health Technology |
Antimicrobials Working Group
Antimicrobials Working Group Miscellaneous Commercial ServicesCommercial Services Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc. | Commercial Services |
| The Agouron Institute | |
| Antibiotics Working Group |
